Promacta

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2015
02420082015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Using data from a large commercial health insurer, we studied prescribing of romiplostim (Nplate) and eltrombopag (Promacta), two… (More)
Is this relevant?
2013
2013
To the Editor.—Eltrombopag (Promacta; 3-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4Hpyrazol-4-ylidene]hydrazino… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2012
Review
2012
Drug developers are grappling with the impact of personalized medicine on their portfolios. The combination of molecular… (More)
Is this relevant?
2010
2010
Thrombocytopenia, a decreased platelet count, is a common clinical feature that may be caused by decreased platelet production or… (More)
Is this relevant?
2010
2010
The Food and Drug Administration recently approved two novel thrombopoiesis-stimulating agents, Romiplostim (AMG-531, Nplate) and… (More)
Is this relevant?
2010
2010
Systemic lupus erythematosus (SLE) is an inflammatory connective tissue disease mediated by a deregulated immune system and… (More)
  • figure 1
  • figure 1
Is this relevant?
2010
2010
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antibodies directed against… (More)
  • figure 2
  • table II
  • figure 2
  • figure 2
Is this relevant?
Review
2009
Review
2009
Platelets play a pivotal role in maintaining hemostatic competence. Thrombocytopenia, irrespective of its etiology, is associated… (More)
Is this relevant?
Review
2008
Review
2008
Various agents to treat immune thrombocytopenic purpura (ITP) have been developed on the principle that stimulating the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?